Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Quiz|Articles|December 14, 2025
Dermatology Times Spot Test: December 14, 2025
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- Hidradenitis suppurativa (HS) involves chronic inflammation, painful nodules, and scarring, primarily in intertriginous areas, with significant impact on quality of life.
- Recent research highlights genetic predispositions, immune dysregulation, and microbiome alterations as key factors in HS pathophysiology.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!
Advertisement
Dermatology Times presents: Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This week, we'll focus on the latest news related to
Do you have a set of quiz questions to share? Contact editor Marie Bosslett at
The global prevalence of HS found in this new study is approximately equivalent to:
What is the theme for Incyte's inaugural HS-focused Ingenuity Awards?
What type of therapeutic is NAV-240?
Advertisement
Related to this article
An HS toolbox with wound care, symptom relief, and personal care supplies can help patients stay prepared for unexpected flares.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Guselkumab met primary and major secondary endpoints in the phase 4 STAR study, improving axial PsA symptoms and MRI-confirmed inflammation.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.
Advertisement
Advertisement
Trending on Dermatology Times
1
From Mechanism to Management: Navigating Male Pattern Hair Loss and New Topical Therapies
2
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
3
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
4
Dr. Charrow Highlights Earlier Biologic Use and Deroofing in Hidradenitis Suppurativa
5